Global Recombinant Human Erythropoietin (rhEPO) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Erythropoietin (rhEPO) Market Research Report 2024
The process of supplying EPO externally, usually with the help of recombinant DNA technology in a cell culture, is known as rhEPO. rhEPO is used to treat anemia due to neural diseases, injuries, kidney diseases or cancer.
According to Mr Accuracy reports new survey, global Recombinant Human Erythropoietin (rhEPO) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Erythropoietin (rhEPO) market research.
Key manufacturers engaged in the Recombinant Human Erythropoietin (rhEPO) industry include 3SBio, Shanghai Chemo, Chengdu Diao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus and Dragon Pharma, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Recombinant Human Erythropoietin (rhEPO) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Human Erythropoietin (rhEPO) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Erythropoietin (rhEPO) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
3SBio
Shanghai Chemo
Chengdu Diao
NCPC Genetech
Kyowa Hakko Kirin
Shandong Kexing
Ahua Pharmaceutical
Biosidus
Dragon Pharma
Segment by Type
ESRD
Cancer
HIV
Wounds and Neural Disease
Hospitals
Retail Pharmacies
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Erythropoietin (rhEPO) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Recombinant Human Erythropoietin (rhEPO) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Erythropoietin (rhEPO) market research.
Key manufacturers engaged in the Recombinant Human Erythropoietin (rhEPO) industry include 3SBio, Shanghai Chemo, Chengdu Diao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus and Dragon Pharma, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Recombinant Human Erythropoietin (rhEPO) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Human Erythropoietin (rhEPO) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Erythropoietin (rhEPO) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
3SBio
Shanghai Chemo
Chengdu Diao
NCPC Genetech
Kyowa Hakko Kirin
Shandong Kexing
Ahua Pharmaceutical
Biosidus
Dragon Pharma
Segment by Type
ESRD
Cancer
HIV
Wounds and Neural Disease
Segment by Application
Hospitals
Retail Pharmacies
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Erythropoietin (rhEPO) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices